CANNAPHARMARX, INC. (CPMD)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 231,608 | 335,319 | 312,164 | - |
| Cost of goods sold | 852,818 | 837,926 | 668,322 | - |
| Gross loss | -621,210 | -502,607 | -356,158 | - |
| Depreciation | - | - | - | 64,237 |
| Payroll and consulting fees | - | - | - | 37,966 |
| General and administrative expense | - | - | - | -6,400 |
| General and administrative | - | - | 51,225 | - |
| Payroll and consulting fees | - | - | 25,389 | - |
| Rent | - | 1,045 | 1,099 | 1,097 |
| Royalty expense | 55,599 | - | - | - |
| Professional fees | 88,219 | 136,337 | 64,075 | 249,662 |
| Payroll and consulting fees | - | - | - | - |
| General and administrative | 75,952 | 27,711 | - | - |
| Amortization and depreciation | - | - | - | - |
| Total operating expenses | 219,770 | 165,093 | 141,788 | 346,562 |
| Loss from operations | -840,980 | -667,700 | -497,946 | -346,562 |
| Other nonoperating expense | - | - | - | 733,718 |
| Loss on extinguishment of debt | - | - | - | -1,368,000 |
| Loss on impairment of inventory | - | - | - | -171,364 |
| Change in the fair value of obligation to issue shares | - | - | - | -673,514 |
| Change in the fair value of obligation to issue shares | - | - | 1,324,327 | - |
| Change in the fair value of obligation to issue shares | - | 1,880,911 | - | - |
| Other expense | - | 1,930,000 | - | - |
| Interest expense | 657,515 | 615,516 | 631,744 | - |
| Loss on the extinguishment of debt | - | - | - | - |
| Change in the fair value of derivative conversion feature | 46,438 | 641,711 | -6,216 | 8,655,422 |
| Foreign exchange gain (loss) | 85,442 | - | - | - |
| Change in the fair value of obligation to issue shares | 46,033 | - | - | - |
| Total other income (expenses) | -572,478 | -22,894 | 686,367 | 5,708,826 |
| Net income (loss) | -1,413,458 | -690,594 | 188,421 | 5,362,264 |
| Foreign currency translation adjustment | -653,505 | -6,891 | - | 58,605 |
| Foreign currency translation adjustment | - | - | -104,442 | - |
| Net comprehensive income (loss) | -2,066,963 | -697,485 | 83,979 | 5,420,869 |
| Basic eps | - | - | - | 0.01 |
| Diluted average shares | - | - | 662,501,405 | 657,980,212 |
| Basic and diluted income (loss) per share of common shares | - | - | - | 0.01 |
| Weighted average number of shares outstanding | 662,501,405 | 662,501,405 | - | 657,980,212 |